Tri-(2-ethylhexyl)trimellitate, also known as TOTM, is a plasticizer commonly used in polyvinyl chloride (PVC) products. It is a synthetic compound synthesized through the esterification of trimellitic anhydride with 2-ethylhexanol. TOTM is highly effective in enhancing the flexibility and durability of PVC, making it a widely used plasticizer in various applications, including flooring, wall coverings, and cable insulation. Due to its potential environmental concerns, particularly its persistence and bioaccumulation in the environment, research on TOTM focuses on understanding its fate and effects on ecosystems, as well as exploring alternative plasticizers with lower environmental impact.'
tri-(2-ethylhexyl)trimellitate: authors commonly refer to it as trioctyl trimellitate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 18725 |
| CHEMBL ID | 1425782 |
| CHEBI ID | 184113 |
| SCHEMBL ID | 34167 |
| MeSH ID | M0110204 |
| Synonym |
|---|
| LS-15354 |
| 1,2,4-benzenetricarboxylic acid, tris(2-ethylhexyl) ester |
| tri(2-ethylhexyl) trimellitate |
| tris(2-ethylhexyl)trimellitate |
| 3319-31-1 |
| NCGC00091597-01 |
| morflex 510 |
| einecs 222-020-0 |
| totm |
| hatcol 200 |
| tri-2-ethylhexyl trimellitate |
| staflex totm |
| brn 2683525 |
| kodaflex totm |
| tri-(2-ethylhexyl)trimellitate |
| ccris 4733 |
| hsdb 6145 |
| monosizer w710l |
| trimex t 08 |
| tris(2-ethylhexyl) trimellitate |
| trioctyl trimellitate, 99% |
| tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate |
| B0881 |
| trioctyl 1,2,4-benzenetricarboxylate |
| 1,2,4-benzenetricarboxylic acid tris(2-ethylhexyl) ester |
| trimellitic acid tris(2-ethylhexyl) ester |
| tri-(2-ethylhexyl) trimellitate |
| FT-0657034 |
| CHEBI:184113 |
| NCGC00091597-02 |
| NCGC00091597-03 |
| ec 222-020-0 |
| 378539q830 , |
| 1,2,4-benzenetricarboxylic acid, 1,2,4-tris(2-ethylhexyl) ester |
| unii-378539q830 |
| cas-3319-31-1 |
| NCGC00254472-01 |
| tox21_202002 |
| dtxcid806265 |
| dtxsid9026265 , |
| NCGC00259551-01 |
| tox21_300614 |
| AKOS015889918 |
| SCHEMBL34167 |
| bisoflex tot (med) |
| pelemol totm |
| tris(2-ethylhexyl) trimellitate [hsdb] |
| triethylhexyl trimellitate [inci] |
| dub tmo |
| triethylhexyl trimellitate |
| 1,2,4-benzenetricarboxylic acid tri(2-ethylhexyl)ester |
| W-106784 |
| CHEMBL1425782 |
| palatinol totm |
| px-338 |
| tri(2-ethylhexyl)trimellitate |
| KRADHMIOFJQKEZ-UHFFFAOYSA-N |
| tris-2-ethylhexyl trimellitate |
| tris(2-ethylhexyl) ester 1,2,4-benzenetricarboxylic acid |
| tricotyl trimellitate |
| tris(2-ethylhexyl) 1,2,4-benzenetricarboxylate # |
| trimellitate tris(2-ethylhexyl) ester |
| plasthall totm |
| tris(2-ethylhexyl) trimellitate, selectophore(tm) |
| mfcd00053799 |
| 1-o,4-o-bis[(2s)-2-ethylhexyl] 2-o-[(2r)-2-ethylhexyl] benzene-1,2,4-tricarboxylate |
| trimellitic acid tri-2-ethylhexyl ester |
| trimellitic acid tris(2-ethylhexyl)ester |
| tri(2-ethyl hexyl) trimellitate |
| BCP15044 |
| tri(2-ethylhexyl) trimellitat |
| Q27256655 |
| F71186 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following iv dosage of 15." | ( Tissue distribution and excretion of tri-(2-ethylhexyl)trimellitate in rats. Freid, E; Martis, L; Woods, E, 1987) | 0.55 |
| Class | Description |
|---|---|
| benzoate ester | Esters of benzoic acid or substituted benzoic acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.2626 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 18.8853 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID588516; AID743035; AID743042; AID743054; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.0158 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 10.8707 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 13.6993 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 20.4992 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743079 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.4332 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 61.6976 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 50.5387 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 5.0119 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 9.6984 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (27.27) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 5 (15.15) | 29.6817 |
| 2010's | 11 (33.33) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (2.86%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (97.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||